Results 151 to 160 of about 34,135 (204)

Implementation of a lifestyle‐based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer [PDF]

, 2019
Bruggeman, Anniek, Bultijnck, Renée, De Muynck, Martine, Decaestecker, Karel, Deforche, Benedicte, Fonteyne, Valerie, Lumen, Nicolaas, Mortier, Stefanie, Ost, Piet, Raes, Anneleen, Rammant, Elke, Van Ruymbeke, Barbara   +11 more
core   +1 more source

Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. [PDF]

Cells
Mortan LF, Isingizwe ZR, Benbrook DM.
europepmc   +1 more source

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance. [PDF]

Cancers (Basel)
Irving E, Morcavallo A, Vohhodina-Tretjakova J, Wijnhoven PWG, Beckett AL, Jacques MP, Evans RS, Moss JI, Staniszewska AD, Forment JV.   +9 more
europepmc   +1 more source

Combination of PARP and KRAS^G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. [PDF]

Nat Commun
Xu X, Chen X, Xu R, Huo Z, Li C, Nowsheen S, Aziz K, Yao F, Lou Z, Deng M.   +9 more
europepmc   +1 more source

Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management. [PDF]

Front Oncol
Park YH, Lee SC, Singer CF, Balmaña J, Dent RA, Tan VK, Mulansari NA, Yusof MM, Que FVF, Lu YS, Parinyanitikul N, Pham CP, Taib NA, Kong SY, Antill Y, Kim HJ.   +15 more
europepmc   +1 more source

Ex Vivo Immuno-Oncology Platform Reveals Spatial T-cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer. [PDF]

Cancer Immunol Res
Sakrepatna Nagaraj A, Salko M, Sirsikar A, Kang Z, Erkan EP, Pietilä EA, Niemiec I, Bao J, Marchi G, Szabó A, Hincapié-Otero M, Lundgren A, Nowlan K, Pikkusaari S, Kanerva A, Tapper J, Koivisto-Korander R, Lassus H, Kauppi L, Hautaniemi S, Vähärautio A, Tang J, Kekäläinen E, Haltia UM, Virtanen A, Jukonen J, Salo T, Färkkilä A.   +27 more
europepmc   +1 more source

DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer. [PDF]

J Exp Clin Cancer Res
Roman C, Sestito R, Caprara V, Sacconi A, Blandino G, Bagnato A, Tocci P.   +6 more
europepmc   +1 more source

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC). [PDF]

J Ovarian Res
Wang L, Xie L, Li Q, Shen Y, Wang H, Sun L, Yang H, Cao D, Li H, Lin B, Chen Q, Guo R, Lou G, Liu Z, Shen Y, Feng W, Zhang P, Zhou J, Wang X, Wang Y, Shen Z, Xue F, Ma L, Tu C, Yang Y, Cheng W, Zhang Y, Kang S, Li C, Wen H, Wu X, Luo X, Yin R, Lin Z.   +33 more
europepmc   +1 more source

Penile metastasis from prostate cancer with CDK12 mutation: A case report and literature review. [PDF]

Oncol Lett
Xiang Q, Wang Y, Yao B, Tang H, Dang Q.
europepmc   +1 more source